JP Morgan Chase’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-56,000
| Closed | -$1.04M | – | 8061 |
|
|
2023
Q3 | $1.04M | Buy |
56,000
+39,800
| +246% | +$450K | ﹤0.01% | 4045 |
|
|
2023
Q2 | $179K | Buy |
+16,200
| New | +$226K | ﹤0.01% | 5143 |
|
|
2023
Q1 | – | Sell |
-4,800
| Closed | -$59K | – | 7400 |
|
|
2022
Q4 | $59K | Sell |
4,800
-94,100
| -95% | -$1.33M | ﹤0.01% | 5563 |
|
|
2022
Q3 | $1.38M | Buy |
98,900
+94,100
| +1,960% | +$1.52M | ﹤0.01% | 3768 |
|
|
2022
Q2 | $66K | Buy |
+4,800
| New | +$76.9K | ﹤0.01% | 5574 |
|
|
2022
Q1 | – | Sell |
-15,300
| Closed | -$249K | – | 7152 |
|
|
2021
Q4 | $249K | Buy |
15,300
+9,200
| +151% | +$155K | ﹤0.01% | 5226 |
|
|
2021
Q3 | $91K | Buy |
+6,100
| New | +$97.6K | ﹤0.01% | 5621 |
|
|
2019
Q2 | – | Sell |
-7,100
| Closed | -$794K | – | 6085 |
|
|
2019
Q1 | $794K | Buy |
+7,100
| New | +$776K | ﹤0.01% | 3939 |
|
|
2018
Q3 | – | Sell |
-30,000
| Closed | -$2.52M | – | 5887 |
|
|
2018
Q2 | $2.52M | Buy |
+30,000
| New | +$2.2M | ﹤0.01% | 3231 |
|
|
2015
Q2 | – | Sell |
-42,800
| Closed | -$12.1M | – | 4231 |
|
|
2015
Q1 | $12.1M | Buy |
+42,800
| New | +$9.27M | ﹤0.01% | 1780 |
|
JP Morgan Chase's ICPT Position: Q4 2023 in Review
JP Morgan Chase sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 289,771 shares — an estimated $5.37M sold.
JP Morgan Chase first reported a position in ICPT in Q2 2013 and held it in 40 quarters. The position peaked at $189M in Q4 2019. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- JP Morgan Chase reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- JP Morgan Chase sold 289,771 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $5.37M.
- JP Morgan Chase first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 40 quarters.
- JP Morgan Chase's Intercept Pharmaceuticals, Inc. position peaked at $189M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.